Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple test predict ovarian cancer treatment success?

NCT ID NCT06152731

Recruiting now Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing two genetic tests (Giscar and myChoice) to see if they can identify ovarian cancer patients whose tumors have a specific DNA repair problem (HRD). The goal is to see if these tests can predict which patients will respond well to platinum chemotherapy and may benefit from PARP inhibitor drugs. The study will enroll 88 women with advanced ovarian cancer who are starting first-line platinum-based chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
genetic tests (Giscar and myChoice) to determine HRD status
What this could lead to
If successful, these tests could help doctors identify which ovarian cancer patients are most likely to benefit from PARP inhibitor treatments, personalizing therapy.
What could go wrong
This is a Phase 2 study with only 88 participants, so results may not apply to all patients. The tests are experimental and may not reliably predict treatment response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal recessive Kenny-Caffey syndrome fallopian tube carcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Francois Baclesse

    RECRUITING

    Caen, France

    Contact

  • Centre Henri Becquerel

    RECRUITING

    Rouen, France

    Contact

  • Centre Oscar Lambret

    RECRUITING

    Lille, France

    Contact

  • Chu Amiens

    NOT_YET_RECRUITING

    Amiens, France

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.